114 related articles for article (PubMed ID: 25596708)
1. [The supply of experimental drugs in a clinical trial: who should pay?].
Lemaire F
Presse Med; 2015 Feb; 44(2):131-4. PubMed ID: 25596708
[No Abstract] [Full Text] [Related]
2. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
3. Innovative Medicines Initiative and antibiotic resistance.
Kostyanev T; Bonten MJ; O'Brien S; Goossens H
Lancet Infect Dis; 2015 Dec; 15(12):1373-5. PubMed ID: 26607115
[No Abstract] [Full Text] [Related]
4. Expanded access to investigational drugs for treatment use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
[TBL] [Abstract][Full Text] [Related]
5. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
6. Individual patient treatment use of unapproved drugs: a new option for the seriously ill.
Simon LS; Green A
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195
[TBL] [Abstract][Full Text] [Related]
7. [French Health Authority guide].
Bouvenot G; Dubernard JM; Rochaix L
Therapie; 2012; 67(5):407. PubMed ID: 23241249
[No Abstract] [Full Text] [Related]
8. Prescription drugs and health care reform.
Gibaldi M
Pharmacotherapy; 1993; 13(6):583-9. PubMed ID: 8302681
[No Abstract] [Full Text] [Related]
9. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
[No Abstract] [Full Text] [Related]
10. [AMNOG: Importance of the identification of target parameters for evidence of clinical effectiveness of innovative drugs].
Meyer F
Dtsch Med Wochenschr; 2012 Jun; 137(23):1268; author reply 1268. PubMed ID: 22644496
[No Abstract] [Full Text] [Related]
11. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
Apel BT
Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
[TBL] [Abstract][Full Text] [Related]
12. Deal watch: Roles and strategies for health foundations in public-private partnerships.
de Vrueh RL; Awad W; Stolk A; Dijcks FA; Rijnders TW; Janssen JW
Nat Rev Drug Discov; 2014 Jun; 13(6):406. PubMed ID: 24875086
[No Abstract] [Full Text] [Related]
13. Should insurance be responsible for the cost of care while a patient is enrolled in a clinical trial?
Weiss PA
Clin J Oncol Nurs; 2008 Feb; 12(1):153-4. PubMed ID: 18258585
[No Abstract] [Full Text] [Related]
14. [Evaluating the effectiveness of drugs. "The full potential of a therapy is often only clear after a number of years" (interview by Helmut Laschet)].
Pfundner H
MMW Fortschr Med; 2010 Dec; 152(51-52):10. PubMed ID: 21294362
[No Abstract] [Full Text] [Related]
15. Drug costs: research and development costs: the great illusion.
Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
[TBL] [Abstract][Full Text] [Related]
16. Trial and error.
Printz C
Cancer; 2013 Feb; 119(3):471-2. PubMed ID: 23341304
[No Abstract] [Full Text] [Related]
17. Is disclosure of potential conflicts of interest in medicine and public health sufficient to increase transparency and decrease corruption?
Spelsberg A; Martiny A; Schoenhoefer PS;
J Epidemiol Community Health; 2009 Aug; 63(8):603-5. PubMed ID: 19596840
[No Abstract] [Full Text] [Related]
18. Learning from the economic crisis: public health and private ventures.
Koch T
J Med Ethics; 2009 Mar; 35(3):145-6. PubMed ID: 19251962
[No Abstract] [Full Text] [Related]
19. [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?].
Schwarz S; Frölich L; Striebel JP; Hennerici MG
Dtsch Med Wochenschr; 2007 Jan; 132(3):108-12. PubMed ID: 17219346
[No Abstract] [Full Text] [Related]
20. How could disclosure of interests work better in medicine, epidemiology and public health: How do potential conflicts of interest confuse medicine and public health?
Marcovitch H
J Epidemiol Community Health; 2009 Aug; 63(8):608-9. PubMed ID: 19596842
[No Abstract] [Full Text] [Related]
[Next] [New Search]
